)
)
)
ExCellThera
ExCellThera is a biotechnology company focused on expanded cell therapies. Its lead asset, Zemcelpro® (UM171 Cell Therapy), received conditional approval from the European Commission in August 2025 as the first and only cell therapy for patients with blood cancers lacking a suitable stem cell donor, setting the stage for commercialization in Europe starting in early 2026.
Address
MontrealQuebec
Canada
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)